Healthcare provider profile · identity verified

Lawrence Wayne Goldstein, MD

Allopathic & Osteopathic Physicians|Family Medicine · TARRYTOWN, NY · NPI 1851478648

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Lawrence Wayne Goldstein, MD received $252.12 in general payments during 2025 across 4 reported records.

Otsuka America Pharmaceutical, Inc. accounted for 64.7% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuedexta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$252.12

4 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$163.22	64.7%	3	2025
Boston Scientific Corporation	Unresolved — no canonical attribution shown	$88.90	35.3%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$252.12	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
REXULTI Normalized: rexulti	Drug	Otsuka America Pharmaceutical, Inc.	$163.22	3	2025
Source payment records 2025-07-30 · Otsuka America Pharmaceutical, Inc. · $24.38 · Open Payments source 2025-09-29 · Otsuka America Pharmaceutical, Inc. · $16.93 · Open Payments source 2025-11-13 · Otsuka America Pharmaceutical, Inc. · $121.91 · Open Payments source
WATCHMAN FLX Normalized: watchman flx	Device	Boston Scientific Corporation	$88.90	1	2025
Source payment records 2025-04-23 · Boston Scientific Corporation · $88.90 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	NUEDEXTA open payments reported associated product	CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901	Nuedexta · 2024 Exact normalized brand match · 1 Part D row	20	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	680	123
Atorvastatin Calcium	Atorvastatin Calcium	512	104
Levothyroxine Sodium	Levothyroxine Sodium	375	68
Tamsulosin Hcl	Tamsulosin Hcl	319	61
Metformin Hcl	Metformin Hcl	296	66
Eliquis	Apixaban	279	40
Gabapentin	Gabapentin	265	46
Escitalopram Oxalate	Escitalopram Oxalate	260	36
Furosemide	Furosemide	257	43
Mirtazapine	Mirtazapine	245	37
Metoprolol Tartrate	Metoprolol Tartrate	238	38
Metoprolol Succinate	Metoprolol Succinate	230	35
Lisinopril	Lisinopril	221	37
Famotidine	Famotidine	218	32
Memantine Hcl	Memantine Hcl	215	19
Rosuvastatin Calcium	Rosuvastatin Calcium	215	49
Donepezil Hcl	Donepezil Hcl	203	24
Pantoprazole Sodium	Pantoprazole Sodium	197	47
Losartan Potassium	Losartan Potassium	169	35
Sertraline Hcl	Sertraline Hcl	161	24
Simvastatin	Simvastatin	151	40
Clopidogrel	Clopidogrel Bisulfate	146	23
Levetiracetam	Levetiracetam	146	11
Divalproex Sodium	Divalproex Sodium	134	14
Meloxicam	Meloxicam	125	40
Jardiance	Empagliflozin	124	19
Carvedilol	Carvedilol	110	21
Quetiapine Fumarate	Quetiapine Fumarate	110	18
Hydrochlorothiazide	Hydrochlorothiazide	107	29
Finasteride	Finasteride	98	14
Carbidopa-Levodopa	Carbidopa/Levodopa	92	suppressed
Ozempic	Semaglutide	90	20
Omeprazole	Omeprazole	87	31
Atenolol	Atenolol	85	26
Montelukast Sodium	Montelukast Sodium	77	17
Allopurinol	Allopurinol	76	17
Citalopram Hbr	Citalopram Hydrobromide	72	suppressed
Aripiprazole	Aripiprazole	70	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	68	26
Duloxetine Hcl	Duloxetine Hcl	67	15
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	65	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	62	16
Arexvy	Rsvpref3 Antigen/As01e/Pf	60	60
Trazodone Hcl	Trazodone Hcl	58	15
Pravastatin Sodium	Pravastatin Sodium	56	suppressed
Spironolactone	Spironolactone	55	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	54	14
Alendronate Sodium	Alendronate Sodium	53	11
Baclofen	Baclofen	53	suppressed
Bupropion Hcl Sr	Bupropion Hcl	50	suppressed
Clonazepam	Clonazepam	50	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	49	suppressed
Oxycodone Hcl	Oxycodone Hcl	49	16
Potassium Chloride	Potassium Chloride	48	suppressed
Januvia	Sitagliptin Phosphate	46	suppressed
Latanoprost	Latanoprost	44	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	11
Primidone	Primidone	42	suppressed
Paroxetine Hcl	Paroxetine Hcl	40	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	39	suppressed
Tizanidine Hcl	Tizanidine Hcl	39	suppressed
Azithromycin	Azithromycin	38	31
Ezetimibe	Ezetimibe	38	suppressed
Torsemide	Torsemide	38	suppressed
Verapamil Er	Verapamil Hcl	38	suppressed
Diclofenac Sodium	Diclofenac Sodium	36	suppressed
Hydralazine Hcl	Hydralazine Hcl	36	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	36	11
Ramipril	Ramipril	36	suppressed
Glipizide	Glipizide	35	suppressed
Metformin Hcl Er	Metformin Hcl	35	suppressed
Risperidone	Risperidone	35	suppressed
Ondansetron Hcl	Ondansetron Hcl	34	11
Xarelto	Rivaroxaban	34	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	33	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	33	26
Diazepam	Diazepam	31	suppressed
Tramadol Hcl	Tramadol Hcl	31	12
Amitriptyline Hcl	Amitriptyline Hcl	30	suppressed
Benztropine Mesylate	Benztropine Mesylate	29	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Nifedipine Er	Nifedipine	29	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	28	suppressed
Fluticasone Propionate	Fluticasone Propionate	28	suppressed
Myrbetriq	Mirabegron	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	27	suppressed
Lorazepam	Lorazepam	26	11
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Albuterol Sulfate	Albuterol Sulfate	25	suppressed
Propranolol Hcl Er	Propranolol Hcl	25	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	24	suppressed
Bupropion Xl	Bupropion Hcl	24	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	24	19
Timolol Maleate	Timolol Maleate	24	suppressed
Darifenacin Er	Darifenacin Hydrobromide	23	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Prednisone	Prednisone	23	suppressed
Ventolin Hfa	Albuterol Sulfate	23	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	22	21
Amantadine	Amantadine Hcl	22	suppressed
Anastrozole	Anastrozole	22	suppressed
Ondansetron Odt	Ondansetron	22	suppressed
Celecoxib	Celecoxib	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Gemtesa	Vibegron	21	suppressed
Misoprostol	Misoprostol	21	suppressed
Betamethasone Valerate	Betamethasone Valerate	20	suppressed
Farxiga	Dapagliflozin Propanediol	20	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	20	suppressed
Alprazolam	Alprazolam	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	14
Enalapril Maleate	Enalapril Maleate	19	suppressed
Olanzapine	Olanzapine	19	suppressed
Amoxicillin	Amoxicillin	18	17
Bisoprolol Fumarate	Bisoprolol Fumarate	18	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	18	suppressed
Irbesartan	Irbesartan	18	suppressed
Lactulose	Lactulose	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Mupirocin	Mupirocin	18	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	17	suppressed
Haloperidol	Haloperidol	17	suppressed
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	12
Divalproex Sodium Er	Divalproex Sodium	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Humulin R	Insulin Regular, Human	16	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Methimazole	Methimazole	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Doxepin Hcl	Doxepin Hcl	15	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Lacosamide	Lacosamide	15	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Sumatriptan	Sumatriptan	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Tacrolimus	Tacrolimus	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Valsartan	Valsartan	15	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	14	suppressed
Sodium Chloride	0.9 % Sodium Chloride	14	suppressed
Bimatoprost	Bimatoprost	13	suppressed
Clotrimazole	Clotrimazole	13	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	13	suppressed
Levofloxacin	Levofloxacin	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Glyburide-Metformin Hcl	Glyburide/Metformin Hcl	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Pregabalin	Pregabalin	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Zoloft	Sertraline Hcl	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Nebivolol Hcl	Nebivolol Hcl	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$252.12 · 4 records	Otsuka America Pharmaceutical, Inc.	REXULTI, WATCHMAN FLX	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error